Which has higher earnings and valuation, URGN or EOLS?

Evolus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $109.79M 19.26 -$153.49M -$1.98 N/A Evolus $297.18M 1.75 -$51.64M -$0.52 N/A

Is URGN or EOLS more profitable?

Evolus has a net margin of -10.85% compared to Urogen Pharma's net margin of -51.73%. Company Net Margins Return on Equity Return on Assets Urogen Pharma -51.73% N/A -43.79% Evolus -10.85% N/A -13.00%

Does the media refer more to URGN or EOLS?

In the previous week, Urogen Pharma had 2 more articles in the media than Evolus. MarketBeat recorded 3 mentions for Urogen Pharma and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Urogen Pharma's score of 0.96 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EOLS or CMPS more profitable?

Compass Pathways has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -10.85% N/A -13.00% Compass Pathways N/A -49.63% -13.08%

Does the media prefer EOLS or CMPS?

In the previous week, Compass Pathways had 6 more articles in the media than Evolus. MarketBeat recorded 7 mentions for Compass Pathways and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Compass Pathways' score of 0.04 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, PRGO or EOLS?

Evolus has lower revenue, but higher earnings than Perrigo. Evolus is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Perrigo $4.25B 0.44 -$1.43B -$12.51 N/A Evolus $297.18M 1.75 -$51.64M -$0.52 N/A

Is PRGO or EOLS more profitable?

Evolus has a net margin of -10.85% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Evolus' return on equity. Company Net Margins Return on Equity Return on Assets Perrigo -41.85% 11.25% 4.08% Evolus -10.85% N/A -13.00%

Does the media prefer PRGO or EOLS?

In the previous week, Perrigo had 3 more articles in the media than Evolus. MarketBeat recorded 4 mentions for Perrigo and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Perrigo's score of 0.45 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GHRS or EOLS more profitable?

GH Research has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Evolus -10.85% N/A -13.00%

Does the media prefer GHRS or EOLS?

In the previous week, GH Research had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for GH Research and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat GH Research's score of 0.58 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ETON or EOLS?

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Evolus. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Eton Pharmaceuticals' score of 1.31 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evolus (EOLS) Competitors

$7.86 -0.15 (-1.87%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.86 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Compare

EOLS vs. URGN, CMPS, PRGO, GHRS, and ETON

Should you buy Evolus stock or one of its competitors? Evolus's main competitors and comparable companies include Urogen Pharma (URGN), Compass Pathways (CMPS), Perrigo (PRGO), GH Research (GHRS), and Eton Pharmaceuticals (ETON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evolus compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and Evolus (NASDAQ:EOLS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Urogen Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Evolus has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

Evolus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	19.26	-$153.49M	-$1.98	N/A
Evolus	$297.18M	1.75	-$51.64M	-$0.52	N/A

Evolus has a net margin of -10.85% compared to Urogen Pharma's net margin of -51.73%.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Evolus	-10.85%	N/A	-13.00%

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Urogen Pharma presently has a consensus price target of $52.38, indicating a potential upside of 21.10%. Evolus has a consensus price target of $14.50, indicating a potential upside of 84.48%. Given Evolus' higher probable upside, analysts clearly believe Evolus is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Urogen Pharma had 2 more articles in the media than Evolus. MarketBeat recorded 3 mentions for Urogen Pharma and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Urogen Pharma's score of 0.96 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evolus beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.

How does Evolus compare to Compass Pathways?

Evolus (NASDAQ:EOLS) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Evolus has higher revenue and earnings than Compass Pathways. Evolus is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.75	-$51.64M	-$0.52	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

90.7% of Evolus shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Compass Pathways has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-10.85%	N/A	-13.00%
Compass Pathways	N/A	-49.63%	-13.08%

Evolus currently has a consensus price target of $14.50, indicating a potential upside of 84.48%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 53.77%. Given Evolus' higher probable upside, equities analysts plainly believe Evolus is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Evolus has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

In the previous week, Compass Pathways had 6 more articles in the media than Evolus. MarketBeat recorded 7 mentions for Compass Pathways and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Compass Pathways' score of 0.04 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Evolus beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does Evolus compare to Perrigo?

Perrigo (NYSE:PRGO) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Evolus has lower revenue, but higher earnings than Perrigo. Evolus is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.44	-$1.43B	-$12.51	N/A
Evolus	$297.18M	1.75	-$51.64M	-$0.52	N/A

Perrigo presently has a consensus target price of $19.33, suggesting a potential upside of 42.29%. Evolus has a consensus target price of $14.50, suggesting a potential upside of 84.48%. Given Evolus' stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Perrigo has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Evolus has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Evolus has a net margin of -10.85% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Evolus	-10.85%	N/A	-13.00%

In the previous week, Perrigo had 3 more articles in the media than Evolus. MarketBeat recorded 4 mentions for Perrigo and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Perrigo's score of 0.45 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evolus beats Perrigo on 10 of the 16 factors compared between the two stocks.

How does Evolus compare to GH Research?

GH Research (NASDAQ:GHRS) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

56.9% of GH Research shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GH Research had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for GH Research and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat GH Research's score of 0.58 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GH Research has higher earnings, but lower revenue than Evolus. GH Research is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Evolus	$297.18M	1.75	-$51.64M	-$0.52	N/A

GH Research presently has a consensus target price of $45.00, suggesting a potential upside of 59.24%. Evolus has a consensus target price of $14.50, suggesting a potential upside of 84.48%. Given Evolus' higher probable upside, analysts clearly believe Evolus is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

GH Research has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Evolus has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

GH Research has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Evolus	-10.85%	N/A	-13.00%

Summary

Evolus beats GH Research on 9 of the 15 factors compared between the two stocks.

How does Evolus compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Evolus. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 1 mentions for Evolus. Evolus' average media sentiment score of 1.43 beat Eton Pharmaceuticals' score of 1.31 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals presently has a consensus target price of $67.50, suggesting a potential upside of 21.62%. Evolus has a consensus target price of $14.50, suggesting a potential upside of 84.48%. Given Evolus' higher possible upside, analysts plainly believe Evolus is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eton Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Evolus has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Eton Pharmaceuticals has a net margin of 12.02% compared to Evolus' net margin of -10.85%. Eton Pharmaceuticals' return on equity of 40.13% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Evolus	-10.85%	N/A	-13.00%

Eton Pharmaceuticals has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	19.84	-$4.60M	$0.38	146.05
Evolus	$297.18M	1.75	-$51.64M	-$0.52	N/A

Summary

Eton Pharmaceuticals beats Evolus on 9 of the 14 factors compared between the two stocks.

Get Evolus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EOLS vs. The Competition

Export

Metric	Evolus	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$519.15M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-15.12	792.21	274.93	25.38
Price / Sales	1.75	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	-21.83	10.53	10.46	6.33
Net Income	-$51.64M	$2.82B	$3.49B	$358.33M
7 Day Performance	0.26%	1.69%	0.59%	1.12%
1 Month Performance	-8.60%	0.83%	-2.01%	-2.67%
1 Year Performance	24.96%	3.90%	18.09%	6.01%

Evolus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EOLS Evolus	3.0692 of 5 stars	$7.86 -1.9%	$14.50 +84.5%	+22.4%	$519.15M	$297.18M	N/A	353	Positive News
URGN Urogen Pharma	2.8834 of 5 stars	$42.64 +0.8%	$52.38 +22.8%	+129.2%	$2.07B	$109.79M	N/A	291
CMPS Compass Pathways	2.4317 of 5 stars	$14.54 +1.3%	$23.36 +60.6%	+199.0%	$1.99B	N/A	N/A	156
PRGO Perrigo	3.4008 of 5 stars	$13.63 -0.2%	$19.33 +41.8%	-36.4%	$1.90B	$4.14B	N/A	8,100	News Coverage Analyst Upgrade
GHRS GH Research	2.3366 of 5 stars	$27.89 +2.5%	$45.00 +61.3%	+113.8%	$1.87B	N/A	N/A	73	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EOLS) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolus (EOLS) Competitors

EOLS vs. URGN, CMPS, PRGO, GHRS, and ETON

How does Evolus compare to Urogen Pharma?

Summary

How does Evolus compare to Compass Pathways?

Summary

How does Evolus compare to Perrigo?

Summary

How does Evolus compare to GH Research?

Summary

How does Evolus compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evolus (EOLS) Competitors

EOLS vs. URGN, CMPS, PRGO, GHRS, and ETON

How does Evolus compare to Urogen Pharma?

Which has more volatility and risk, URGN or EOLS?

Which has higher earnings and valuation, URGN or EOLS?

Is URGN or EOLS more profitable?

Do institutionals and insiders believe in URGN or EOLS?

Do analysts prefer URGN or EOLS?

Does the media refer more to URGN or EOLS?

Summary

How does Evolus compare to Compass Pathways?

Which has stronger earnings and valuation, EOLS or CMPS?

Do institutionals & insiders believe in EOLS or CMPS?

Is EOLS or CMPS more profitable?

Do analysts recommend EOLS or CMPS?

Which has more risk and volatility, EOLS or CMPS?

Does the media prefer EOLS or CMPS?

Summary

How does Evolus compare to Perrigo?

Which has stronger earnings and valuation, PRGO or EOLS?

Do analysts prefer PRGO or EOLS?

Which has more risk & volatility, PRGO or EOLS?

Do insiders and institutionals hold more shares of PRGO or EOLS?

Is PRGO or EOLS more profitable?

Does the media prefer PRGO or EOLS?

Summary

How does Evolus compare to GH Research?

Do insiders & institutionals have more ownership in GHRS or EOLS?

Does the media prefer GHRS or EOLS?

Which has preferable valuation & earnings, GHRS or EOLS?

Do analysts prefer GHRS or EOLS?

Which has more volatility and risk, GHRS or EOLS?

Is GHRS or EOLS more profitable?

Summary

How does Evolus compare to Eton Pharmaceuticals?

Does the media prefer ETON or EOLS?

Do analysts prefer ETON or EOLS?

Do insiders and institutionals have more ownership in ETON or EOLS?

Which has more volatility & risk, ETON or EOLS?

Is ETON or EOLS more profitable?

Which has better valuation and earnings, ETON or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools